3CL protease inhibitor NLC-001 added to COVID-19-focused joint venture between Todos Medical and NLC Pharma
On Sept. 17, 2020, Todos Medical announced that NLC Pharma had added the dietary supplement NLC-001 to its…
-
-
T cells take the lead in controlling SARS-CoV-2 and reducing COVID-19 disease severity
On Sept. 16, 2020, a study by researchers at La Jolla Institute for Immunology published in the Cell,…
-
NanoViricides nominated a novel candidate for advancing Into clinical trials for treatment of COVID-19
On Sept. 16, 2020, NanoViricides announced that it had nominated a clinical drug candidate for the treatment of…
-
AIM ImmunoTech announced start of recruitment in clinical trial incorporating Ampligen in treatment of cancer patients with COVID-19
On Sept. 16, 2020, AIM ImmunoTech announced that recruitment had begun in Roswell Park Comprehensive Cancer Center’s Phase…
-
COVID-19 | FDA | Therapeutics
AXIM Biotechnologies filed Emergency Use Authorization with COVID-19 rapid diagnostic test for neutralizing antibodies
On Sept. 16, 2020, AXIM Biotechnologies announced that it had filed an Emergency Use Authorization (EUA) application with…
-
Laboratory testing of Brilacidin for COVID-19 in combination with remdesivir reduces viral load by nearly 100 percent
On Sept. 15, 2020, Innovation Pharma reported additional data from a U.S. Regional Biocontainment Laboratory (RBL) collected during…
-
FDA contracted with global partners to analyze coronavirus samples
On Sept. 15, 2020, the FDA awarded a $5.4 million research contract to the University of Liverpool and…
-
Soligenix announced publication demonstrating thermostabilization of filovirus vaccine antigens
On Sept. 15, 2020, Soligenix announced publication of nonclinical results characterizing filovirus protein antigens (including for Ebola and…
-
Tonix Pharma enrolled first patient in COV-LOGIC study to assess antibody and T cell responses to SARS-CoV-2
On Sept. 15, 2020,Tonix Pharmaceuticals announced that the first patient was enrolled in the observational COV-LOGIC study (TNX-C001),…
-
Genomic leaders collaborated to create Australia’s first national COVID-19 tracking system
On Sept. 14, 2020, Illumina announced that the Australian public health laboratories will aim to sequence the virus…
-
Meridian launched novel SARS-CoV-2 antibody pair designed for developing highly sensitive rapid antigen tests from saliva
On Sept. 14, 2020, Meridian Bioscience announced the launch of a novel highly sensitive SARS-CoV-2 antibody pair to…
-
COVID-19 vaccine AZD1222 clinical trials resumed in the UK
On Sept. 12 2020, Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK…
-
Transmission of COVID-19 outbreaks associated with child care facilities in Utah
On Sept. 11, 2020, the CDC reported that twelve children acquired COVID-19 in child care facilities. One parent…
-
Fosun Pharma announced novel Coronavirus (2019-nCoV) RT-PCR detection Kit included in WHO Emergency Use Listing
On Sept. 10, 2020, Shanghai Fosun Pharmaceutical announced that the Novel Coronavirus (2019-nCoV) RT-PCR Detection Kit self-developed by…
-
Pfizer and BioNTech announced data from preclinical studies of mRNA-based vaccine candidate against COVID-19
On Sept. 9, 2020, Pfizer and BioNTech announced preliminary preclinical data in mouse and non-human primate models from…
-
BioNTech and Pfizer announced data from preclinical studies of mRNA-based vaccine candidate against COVID-19
On Sept. 9, 2020, Pfizer and BioNTech announced preliminary preclinical data in mouse and non-human primate models from…
-
AstraZeneca Oxford SARS-CoV-2 vaccine, AZD1222, COVID-19 vaccine trials temporary paused
On Sept. 9, 2020, as part of the ongoing randomised, controlled clinical trials of the AstraZeneca Oxford coronavirus…
-
RedHill Biopharma’s opaganib demonstrated complete inhibition of SARS-CoV-2
On Sept. 8, 2020, RedHill Biopharma announced that opaganib demonstrated potent inhibition of SARS-CoV-2, the virus that causes…
-
Biotechnology | COVID-19 | Infectious Disease | Life Science History | Medicine | Non-Profit Research | Stem Cell | Therapeutics
California’s Stem Cell Agency and the Chan Zuckerberg Initiative partnered to create COVID-19 database
On Sept. 8, 2020, a new collaboration between the California Institute for Regenerative Medicine (CIRM) and the Chan…
-
Vaxartﾒs oral COVID-19 vaccine candidate induced potent systemic and mucosal immune responses in preclinical studies
On Sept. 8, 2020, Vaxart announced pre-publication of a manuscript titled ﾓPreclinical studies of a recombinant adenoviral mucosal…
-
Johnson & Johnson announced COVID-19 investigational vaccine candidate prevents severe clinical disease in hamsters
On Sept. 3, 2020, as part of the ongoing randomised, controlled clinical trials of the AstraZeneca Oxford coronavirus…
-
COVID-19 vaccine study shows severe disease preventable in hamsters
On Sept. 3, 2020, Oregon Health & Science University (OHSU) announced that for the first time, early research…
-
Virginia Tech researchers began testing campus wastewater for COVID-19
On Sept. 3, 2020, a team of Virginia Tech researchers announced that they will begin testing wastewater at…
-
NIH-supported study to track prevalence and impact of SARS-CoV-2 among pregnant women in low- and middle-income countries
On Sept. 1, 2020, the National Institutes of Health announced that it had launched a study to track…
-
Phase 3 clinical testing in the US of AstraZeneca COVID-19 vaccine candidate began
On Aug. 31, 2020, a multi-site, Phase 3 clinical trial evaluating an investigational COVID-19 vaccine known as AZD1222…
-
Development of COVID-19 vaccine AZD1222 expanded into U.S. Phase III clinical trial across all adult age groups
On Aug. 31, 2020, AstraZeneca announced that the COVID-19 vaccine AZD1222 expanded into U.S. Phase III clinical trial…
-
Vir Biotechnology and GSK started phase 2/3 study of COVID-19 antibody treatment
On Aug. 31, 2020, Vir Biotechnology and GlaxoSmithKline announced that the first patient was dosed in a phase…
-
T2 Biosystems received FDA Emergency Use Authorization for COVID-19 molecular diagnostic test
On Aug. 31, 2020, T2 Biosystems announced that the FDA had issued an Emergency Use Authorization (EUA) for…
-
Disease | NIH | Therapeutics
NIAID awarded BioCryst $44 million contract to advance development of galidesivir
On Aug. 31, 2020, BioCryst Pharmaceuticals announced that the National Institute of Allergy and Infectious Diseases (NIAID) had…
-
iBio and Planet Biotechnology entered into exclusive worldwide license agreement for development of a COVID-19 therapeutic
On Aug. 28, 2020, iBio announced that it had entered into an exclusive worldwide license agreement with Planet…
